Cybin Inc N.CYBN

Alternate Symbol(s): CYBN

Healthcare Drug Manufacturers - Specialty & Generic

Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

NEO:CYBN - Post by User

Cybin Inc > Overview of Adelia Science Team that brings value to Cybin

<< Previous

Bullboard Posts

Next >>

Post by Streetbrainon Dec 13, 2020 2:45pm

192 Views

Post# 32096085

Overview of Adelia Science Team that brings value to Cybin

Alex Nivorozhkin, PhD. - https://www.researchgate.net/profile/Alex_Nivorozhkin

Michael G. Palfreyman, PhD, DSc - Michael is a co-inventor on 43 issued patents and co-author of more than 150 publications. Michael holds a D.Sc. (1996) in rational design of CNS drugs; a Ph.D. (1970) degree in Neuroscience and Neuropharmacology, as well as a B. Pharm (Magna Laude, 1967 in Pharmacy), and MRPharmS (Pharmacy Practice, 1971), .

Alex Belser, PhD -https://alexbelser.com/work.html

Clinton E. Canal, PhD -https://www.researchgate.net/profile/Clinton_Canal

Brett J. Greene - https://bouve.northeastern.edu/bchs/directory/brett-greene/

<< Previous

Bullboard Posts

Next >>

Mullen Group: Navigates market challenges towards success